drugset

drugset / Trial / NCT00002249

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

NCT00002249 ↗

Phase 1 Completed R W Johnson Pharmaceutical Research Institute

Double-blindTreatment

Summary

To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.

Timeline

Start: —
Primary completion: —
Completion: —

Publications

Background Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1994 Apr;38(4):799-804. doi: 10.1128/AAC.38.4.799.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levofloxacin	Small molecule	—	—

Indications